Breakdown |
---|
Income Statement |
Total Revenue |
Gross Profit |
EBITDA |
Net Income |
Balance Sheet |
Total Assets |
Cash, Cash Equivalents and Short-Term Investments |
Total Debt |
Total Liabilities |
Stockholders Equity |
Cash Flow |
Free Cash Flow |
Operating Cash Flow |
Investing Cash Flow |
Financing Cash Flow |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $4.79B | 21.19 | 29.85% | ― | 6.31% | 11.24% | |
76 Outperform | $4.14B | 19.10 | 16.62% | ― | 13.10% | 127.72% | |
72 Outperform | $4.01B | 6.44 | 14.87% | 0.78% | 5.91% | 137.49% | |
71 Outperform | $1.86B | 12.56 | 16.54% | 1.83% | 6.35% | 0.35% | |
69 Neutral | $1.89B | 16.79 | 6.86% | 3.06% | 5.72% | 11.02% | |
68 Neutral | $3.43B | 12.27 | 31.14% | ― | 1.26% | 140.30% | |
63 Neutral | $17.26B | 10.39 | -8.50% | 3.06% | 1.63% | -25.95% |
On June 10, 2025, Stephen W. Beard, CEO of Adtalem Global Education, initiated a 10b5-1 trading plan to sell up to 108,000 shares of the company’s common stock. This plan, compliant with the Securities Exchange Act, allows for sales if certain price thresholds are met, with the first potential sale not before September 12, 2025. The plan will not affect Beard’s compliance with stock ownership guidelines and is set to terminate on May 29, 2026.
The most recent analyst rating on (ATGE) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Adtalem Global Education stock, see the ATGE Stock Forecast page.
On May 6, 2025, Adtalem Global Education announced a new $150 million share repurchase program authorized by its board of directors, allowing the company to buy back shares through May 2028. This follows the completion of a previous $300 million repurchase program, reflecting Adtalem’s strong financial position and commitment to shareholder value. The company has returned $763 million to shareholders since February 2022, reducing shares outstanding by 28%. Adtalem aims to leverage its robust cash flow to expand healthcare education programs and continue enhancing shareholder value.